Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Gene expression profiling of Burkholderia cenocepacia at the time of cepacia syndrome: loss of motility as a marker of poor prognosis

L. Kalferstova, M. Kolar, L. Fila, J. Vavrova, P. Drevinek,

. 2015 ; 53 (5) : 1515-1522. [pub] 20150218

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000275

Grantová podpora
NT12405 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje NLK Online Plný text

Free Medical Journals od 1975 do Před 6 měsíci
Freely Accessible Science Journals od 1995 do Před 6 měsíci
PubMed Central od 1975 do Před 6 měsíci
Europe PubMed Central od 1975 do Před 6 měsíci
Open Access Digital Library od 1975-01-01
Open Access Digital Library od 1975-01-01

Cepacia syndrome (CS) is a fatal septic condition that develops in approximately 20% of cystic fibrosis (CF) patients chronically infected with the Burkholderia cepacia complex (Bcc). The most common causative agent is Burkholderia cenocepacia, a clinically dominant Bcc species that contains the globally distributed epidemic strain sequence type 32 (ST32). Using microarrays, we compared the transcriptomes of ST32 isolates from the bloodstream at the time of CS with their sputum counterparts recovered 1 to 2 months prior to the development of CS. Global gene expression profiles of blood isolates revealed greater activities of the virulence genes involved in the type III secretion system, the bacterial exopolysaccharide cepacian, and quorum sensing, while reduced expression was demonstrated for flagellar genes. Furthermore, a nonmotile phenotype (as evaluated by a swimming motility assay) was identified in blood isolates from 6 out of 8 patients with CS; this phenotype was traceable to 24 months prior to the onset of CS. Loss of motility was not observed in any of the 89 ST32 isolates recovered over the course of chronic infection from 17 patients without CS. In conclusion, the gene expression of Bcc bacteria disseminated during CS has been elucidated for the first time. This study demonstrated marked differences at the transcriptome level between isogenic ST32 isolates that are attributable to the stage and site of infection. The finding of a nonmotile B. cenocepacia isolate may serve as a warning sign for the development of CS in the near future.

000      
00000naa a2200000 a 4500
001      
bmc16000275
003      
CZ-PrNML
005      
20200121091815.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1128/JCM.03605-14 $2 doi
035    __
$a (PubMed)25694518
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kalferstová, Lucie, $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. $d 1986- $7 xx0206973
245    10
$a Gene expression profiling of Burkholderia cenocepacia at the time of cepacia syndrome: loss of motility as a marker of poor prognosis / $c L. Kalferstova, M. Kolar, L. Fila, J. Vavrova, P. Drevinek,
520    9_
$a Cepacia syndrome (CS) is a fatal septic condition that develops in approximately 20% of cystic fibrosis (CF) patients chronically infected with the Burkholderia cepacia complex (Bcc). The most common causative agent is Burkholderia cenocepacia, a clinically dominant Bcc species that contains the globally distributed epidemic strain sequence type 32 (ST32). Using microarrays, we compared the transcriptomes of ST32 isolates from the bloodstream at the time of CS with their sputum counterparts recovered 1 to 2 months prior to the development of CS. Global gene expression profiles of blood isolates revealed greater activities of the virulence genes involved in the type III secretion system, the bacterial exopolysaccharide cepacian, and quorum sensing, while reduced expression was demonstrated for flagellar genes. Furthermore, a nonmotile phenotype (as evaluated by a swimming motility assay) was identified in blood isolates from 6 out of 8 patients with CS; this phenotype was traceable to 24 months prior to the onset of CS. Loss of motility was not observed in any of the 89 ST32 isolates recovered over the course of chronic infection from 17 patients without CS. In conclusion, the gene expression of Bcc bacteria disseminated during CS has been elucidated for the first time. This study demonstrated marked differences at the transcriptome level between isogenic ST32 isolates that are attributable to the stage and site of infection. The finding of a nonmotile B. cenocepacia isolate may serve as a warning sign for the development of CS in the near future.
650    _2
$a dospělí $7 D000328
650    _2
$a bakteriemie $x mikrobiologie $7 D016470
650    _2
$a krev $x mikrobiologie $7 D001769
650    _2
$a infekce bakteriemi rodu Burkholderia $x mikrobiologie $7 D019121
650    _2
$a Burkholderia cenocepacia $x genetika $x fyziologie $7 D057508
650    _2
$a cystická fibróza $x komplikace $x mikrobiologie $7 D003550
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a flagella $x genetika $x fyziologie $7 D005407
650    12
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a lokomoce $7 D008124
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikročipová analýza $7 D046228
650    12
$a biogeneze organel $7 D001678
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sputum $x mikrobiologie $7 D013183
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kolar, Michal $u Institute of Molecular Genetics, Academy of Sciences, Prague, Czech Republic.
700    1_
$a Fila, Libor $u Department of Pneumology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Vavrová, Jolana, $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. $d 1989- $7 xx0207034
700    1_
$a Dřevínek, Pavel, $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic pavel.drevinek@lfmotol.cuni.cz. $d 1975- $7 xx0075827
773    0_
$w MED00002592 $t Journal of clinical microbiology $x 1098-660X $g Roč. 53, č. 5 (2015), s. 1515-1522
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25694518 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200121092152 $b ABA008
999    __
$a ok $b bmc $g 1102556 $s 924481
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 53 $c 5 $d 1515-1522 $e 20150218 $i 1098-660X $m Journal of clinical microbiology $n J Clin Microbiol $x MED00002592
GRA    __
$a NT12405 $p MZ0
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...